Drug Database
PA

paliperidone

✓ Approved

Torrent Pharmaceuticals Limited · DRD2 · 小分子

什么是 paliperidone?

paliperidone 是一种小分子,由Torrent Pharmaceuticals Limited研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

公司Torrent Pharmaceuticals Limited
药物类别小分子
分子靶点DRD2, HTR2A, HTR7
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

paliperidone 作用于 3 个分子靶点:

DRD2dopamine receptor D2 (D2DR, D2R)
HTR2A5-hydroxytryptamine receptor 2A (5-HT2A, HTR2)
HTR75-hydroxytryptamine receptor 7 (5-HT7)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

paliperidone 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Psychiatric disordersSchizophrenia✓ Approved

相关研究文献

PubMedTherapeutic advances in psychopharmacology2026-11-18

Impulse control symptoms associated with aripiprazole long-acting injectable: A prospective cohort study.

López García Francisco José FJ, de Marco Galliano Guido G, López Soto Melisa Darlene MD, Vallès Callol Vicenç V et al.

Impulse control disorders (ICDs) have been described in association with dopamine partial agonists, particularly aripiprazole. However, data regarding the risk of ICDs with long-acting injectable (LAI) formulations remain limited. To prospectively examine the presence and course of impulse control symptoms in psychiatric patients treated with intramuscular aripiprazole, compared with paliperidone and risperidone, over six months of follow-up. Prospective cohort study. We conducted a prospective cohort study in a naturalistic clinical setting to evaluate the emergence of impulse control symptoms in patients treated with aripiprazole LAI. 27 patients initiating intramuscular treatment with aripiprazole (n=17), paliperidone (n=6), or risperidone (n=4) were systematically assessed monthly for pathological gambling, compulsive buying, hypersexuality, alcohol use, and other substance use. Repeated-measures ANOVA and linear mixed-effects models were applied. Clinically significant impulse control symptoms emerged in a proportion of patients treated with aripiprazole LAI, particularly compulsive buying. Symptom presentation was heterogeneous. While most monitored behaviours followed comparable longitudinal trajectories across treatment groups, compulsive buying showed a significant group-by-time interaction, characterized by a peak at month 3 among patients receiving aripiprazole. These findings suggest that aripiprazole LAI may be associated with the emergence of impulse control symptoms in a subset of patients. Although preliminary, this study highlights the importance of systematic monitoring of behavioral side effects in patients receiving LAI formulations of dopamine partial agonists. Further research with larger samples is warranted to better characterize this association.

PMID 43047689
阅读全文 →
PubMedNeuroscience2026-11-18

Advanced nanodispersion systems for antipsychotic drug delivery: mechanistic advances, translational challenges, and future perspectives.

Govindan Deepa D, Kannan Suriya Prakaash SP, Narayanasamy Damodharan D

Antipsychotic therapy remains central to schizophrenia management; however, poor aqueous solubility, variable systemic exposure, dose-related adverse effects, and poor treatment adherence continue to limit therapeutic outcomes. Advanced nanodispersion systems, including nanosuspensions, liposomes, solid lipid nanoparticles, nanostructured lipid carriers, self-emulsifying drug delivery systems, and lipid-polymer hybrid nanoparticles, have emerged as promising approaches to address these limitations. This review critically evaluates these platforms by integrating formulation characteristics, administration routes, pharmacokinetic performance, therapeutic evidence, and translational feasibility. Importantly, the available evidence reveals a substantial gap between experimental performance and clinical validation. Nanocrystal-based long-acting injectable antipsychotics, particularly paliperidone palmitate formulations, have demonstrated sustained systemic exposure and clinically established therapeutic benefits. Aripiprazole lauroxil NanoCrystal Dispersion has also achieved clinical application as a treatment-initiation formulation. In contrast, reported improvements in blood-brain barrier transport, brain drug accumulation, and pharmacological responses associated with emerging lipid-based and hybrid nanocarriers remain predominantly supported by in vitro and animal studies. These findings do not independently establish improved clinical efficacy, reduced adverse effects, or better patient outcomes. Major translational barriers include formulation instability, sterilization compatibility, manufacturing reproducibility, long-term safety, and limited human clinical evidence. Patient safety, consistent product quality, and rigorous clinical validation are identified as critical priorities for future development. No single nanodispersion platform is universally superior; rational platform selection requires consideration of drug properties, administration route, therapeutic objectives, and the strength of supporting evidence. This review highlights the distinction between established clinical applications and experimental nanocarrier technologies while identifying priorities for advancing antipsychotic nanodispersions toward clinical translation.

PMID 43051579
阅读全文 →
PubMedJournal of psychiatric practice2026-11-11

Psychosis With Cognitive Impairment in a Young Adult: Case Report.

Ribeiro Marta M, Francisco Santos Silva SS, Inês Braz B

Cognitive symptoms are an often-undervalued dimension of psychotic disorders that are overshadowed by positive symptoms that are more striking and more the target of treatment. Nevertheless, cognitive symptoms affect up to 80% of patients with primary psychotic disorders and exert a decisive impact on prognosis, quality of life, and functional outcomes. Processing speed, attention, and memory are the most consistently affected domains, with greater impairment observed in individuals with predominantly negative symptoms. Cognitive deficits often predate the onset of the first episode of psychosis, but their long-term trajectory remains the subject of debate, which oscillates between neurodevelopmental and neurodegenerative models. Importantly, cognitive dysfunction in schizophrenia is broader and more persistent than in affective psychoses and shows limited improvement with antipsychotic treatment. We report the case of a 19-year-old woman with a first episode of psychosis who presented with predominantly positive symptoms along with profound cognitive impairment. Neuropsychological assessment revealed severe deficits in attention, fluency, memory, and executive functioning, with a Montreal Cognitive Assessment score of 12/30 during her acute presentation. Extensive workup excluded other physical and autoimmune etiologies, although cranial MRI showed bilateral mesiotemporal atrophy, a finding consistent with cognitive dysfunction in psychotic spectrum disorders. Treatment with paliperidone led to remission of psychotic symptoms and partial cognitive improvement (Montreal Cognitive Assessment 21/30), yet substantial deficits persisted, impacting autonomy, insight, and social functioning. This case illustrates the emblematic role of cognitive impairment in psychotic disorders, highlighting its early onset, persistence despite symptomatic remission, and limited responsiveness to dopamine-targeted treatments. Emerging therapies-such as modulators of the cholinergic system, erythropoietin derivatives, and cognitive remediation strategies-represent promising avenues to address these unmet needs.

PMID 43013866
阅读全文 →
PubMedInternational journal of psychiatry in clinical practice2026-11-09

The relationship of LAI paliperidone and LAI aripiprazole plasma levels to their efficacy and tolerability: data from EULAST.

Ustohal Libor L, Obdržálková Marie M, Jáni Martin M, Horská Kateřina K

Poor adherence in schizophrenia is often solved by long-acting injectable (LAI) medication. Even LAIs need to be individualised through dosing adjustments to ensure efficacy and safety. It can be achieved by implementing therapeutic drug monitoring (TDM). That's why we decided to analyse data from the EULAST study. Data from 180 patients who were randomised to one of the LAI groups were used in this study. Their plasma levels at the beginning, throughout and at the end of the study were analysed, and their relationships with efficacy, extrapyramidal side effects, functional status and quality of life were assessed. At the beginning, a significant number (56.1%) of all patients had subtherapeutic plasma levels, during the study 41% of patients had subtherapeutic plasma levels, and at the end, 26.7%. Only a minimum of patients had supratherapeutic plasma levels. No substantial evidence for the relationship between LAI type, plasma level range and treatment outcomes, including efficacy, side effects, functional status and quality of life, was found. Our data did not confirm the impact of LAIs' plasma levels on treatment outcomes. It seems beneficial to revise and reconsider the therapeutic reference range for LAIs; however, further studies are needed.

PMID 43002074
阅读全文 →
PubMedSchizophrenia research2026-11-06

Structural brain age trajectories in antipsychotic-naive first episode psychosis.

Roig-Herrero Alejandro A, Francey Shona M SM, O'Donoghue Brian B, Nelson Barnaby B et al.

Psychotic disorders such as schizophrenia have been associated with older-appearing brain structure, commonly quantified using the brain-age paradigm. However, it remains unclear whether these alterations are present at illness onset and whether antipsychotic treatment modifies their trajectory. In this study, 61 (28 females and 33 males) antipsychotic-naïve people with first-episode psychosis were randomized to receive either a second-generation antipsychotic (risperidone or paliperidone) or placebo over a 6-month treatment period, alongside intensive psychosocial therapy. A healthy control group (n = 27, 17 females, 10 males) was also recruited. Structural MRI scans were collected at baseline, 3 months, and 12 months. Brain age was estimated using two pretrained and validated models (Pyment and CentileBrain). Brain-predicted age difference (brain-PAD) did not differ between patients and healthy controls at baseline (F(1,80) = 0.81, p = 0.37). There were also no significant effects of time, treatment group (antipsychotic, placebo, healthy control), or their interaction on brain-PAD across the first year (all p > 0.26). Findings were consistent across both brain-age models, and brain-PAD was not associated with clinical and lifestyle measures. These findings suggest that altered structural brain aging is not evident during the earliest stages of psychosis and is not modified by early antipsychotic exposure over the first year of illness. Longer follow-up and approaches that account for illness heterogeneity may be needed to clarify when brain-age alterations emerge in psychotic disorders. Australian New Zealand Clinical Trials Registry (http://www.anzctr.org.au/; ACTRN12607000608460).

PMID 42994381
阅读全文 →
PubMedJournal of clinical psychopharmacology2026-11-03

Six-Monthly Formulation of Paliperidone Palmitate in Delusional Disorder: First Case Report.

Cunha Mário Jorge Martins Rodrigues da MJMRD, Velosa Ana Patrícia Santos APS

PMID 42975411
阅读全文 →

注册免费账户还可查看另外 1835 篇文献

免费注册查看全部文献 →

了解更多paliperidone